Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 06/13/2007, Updated: 11/01/2010) - Infants and children with intermediate-risk neuroblastoma who received a less-intensive chemotherapy regimen had three-year overall survival rates as good as those patients in an earlier trial who received treatment that was more intensive and more toxic, according to findings presented at the 2007 ASCO meeting in Chicago.
Hormone Therapy Linked to Modest Increase in Breast Cancer Deaths
(Posted: 10/20/2010) - Women who used combined estrogen and progestin hormone replacement therapy to treat menopausal symptoms during the Women’s Health Initiative (WHI) study had more cases of invasive breast cancer, more lymph-node positive breast cancer, and a slightly higher death rate from breast cancer and other causes than women who received a placebo, researchers reported in an 11-year follow-up report on the study's participants.
Breast Cancer Drug Helps Patients with Gastric Cancer
(Posted: 06/19/2009, Updated: 10/01/2010) - Patients with advanced gastric cancer who received standard chemotherapy plus trastuzumab (Herceptin®) survived several months longer than those who received chemotherapy alone, according to findings presented at the 2009 ASCO meeting in Orlando.
Addition of immunotherapy boosts pediatric cancer survival:
(Posted: 09/29/2010) - Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study in the Sept. 30, 2010, New England Journal of Medicine.
Reducing Treatment Intensity Doesn't Compromise Results in Early-Stage Hodgkin Lymphoma
(Posted: 09/27/2010) - Reducing the dose of chemotherapy and radiotherapy did not compromise treatment efficacy in patients with early-stage, low-risk Hodgkin lymphoma but led to fewer side effects, according to a study published August 12, 2010, in the New England Journal of Medicine.